Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients
Study Details
Study Description
Brief Summary
The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.Study hypothesis: The aqueous humor concentration 45 minutes following dosing of 0.1% Brimonidine Purite™ (pH 7.8) is comparable with 0.15% Brimonidine Purite® (pH 7.2)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.
Study Design
Outcome Measures
Primary Outcome Measures
- Bioanalysis of brimonidine concentrations. []
Eligibility Criteria
Criteria
Inclusion Criteria:
- All subjects must:
-
Be willing and able to provide written Informed Consent
-
Be able and willing to follow instructions and likely to complete the entire course of the study.
-
Be male or female of any race at least 18 years of age.
-
Have visually significant cataract for which they have elected to undergo cataract surgery.
Exclusion Criteria:
- No subject may:
-
Known allergy or sensitivity to the study medication or its components
-
Contraindications to brimonidine therapy: concurrent use of monoamine oxidase (MAO) inhibitor therapy
-
Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Patients with mild chronic blepharitis, age-related macular degeneration, background diabetic retinopathy may be enrolled at the discretion of the investigator.
-
Any ocular surgery (including laser, refractive, intraocular filtering surgery, or any other ocular surgery) within 3 months.
-
Require use of ocular medications (including glaucoma medications), except intermittent use of artificial tears.
-
Have corneal abnormalities that would interfere with the ability to obtain an adequate sample safely or have a shallow anterior chamber which would make obtaining an aqueous sample difficult at the time of surgery in the opinion of the investigator.
-
Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.
-
Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception.
-
Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study such as, significant cardiovascular disease, hepatic or renal impairment, depression, Raynaud's, orthostatic hypotension; uncontrolled high blood pressure. or concomitant use of other potential CNS depressants and tricyclics, (Amendment 1, May 25, 2005)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital | Indianapolis | Indiana | United States | 46202 |
| 2 | Veterans Affairs Medical Center | Indianapolis | Indiana | United States | 46202 |
| 3 | Wishard Memorial Hospital | Indianapolis | Indiana | United States | 46202 |
| 4 | Iu Eye at Carmel | Indianapolis | Indiana | United States | 46290 |
Sponsors and Collaborators
- Indiana University School of Medicine
- Allergan
Investigators
- Principal Investigator: Louis B Cantor, MD, IUPUI/Clarian
Study Documents (Full-Text)
None provided.More Information
Publications
- PK-02-P027 Relative ocular bioavailability of 0.2% Alphagan and 0.15% Brimonidine-BAK to that of 0.15% Alphagan P in female albino rabbits. Allergan 2002.
- PK-02-P041 Comparison of ocular and systemic bioavailability of three 0.10% brimonidine purite formulations to that of 0.15% Alphagan P in albino rabbits. Allergan 2002.
- 0501-45